Epitome Biosystems Overview

  • Founded
  • 2004
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Epitome Biosystems General Information


Developer of technology to measure protein biomarkers and intracellular infrastruture. The company has developed a system using antibody microarrays to provide measurement of protein biomarkers and intracellular signalling pathways.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • 100 Beaver Street
  • Waltham, MA 02453
  • United States
+1 (781) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Epitome Biosystems Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 02-Mar-2009 000.00 Completed Product Development
3. Early Stage VC (Series A1) 08-Dec-2008 000.00 000.00 000.00 Completed Product Development
2. Debt - General 11-Apr-2008 $1M $4.94M Completed Product Development
1. Early Stage VC (Series A) 16-Nov-2004 $3.94M $3.94M 00.000 Completed Product Development
To view Epitome Biosystems’s complete valuation and funding history, request access »

Epitome Biosystems Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A1 0,000,000 00.000000 00 00 00 00 00 00.00
Series A 0,000,000 00.000000 00 00 00 00 00 000
To view Epitome Biosystems’s complete cap table history, request access »

Epitome Biosystems Executive Team (2)

Name Title Board Seat Contact Info
Neal Gordon President
You’re viewing 1 of 2 executive team members. Get the full list »

Epitome Biosystems Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Flagship Pioneering Venture Capital Minority 000 0000 000000 0
To view Epitome Biosystems’s complete investors history, request access »